Logo
x

Search

Subscribe Now

HUTCHMED

HUTCHMED Secures $10M Milestone Payment from Takeda Following the First Reimbursement of Fruzaqla in Europe

HUTCHMED Secures $10M Milestone Payment from Takeda Following the First Reimbursement of Fruzaqla in Europe

  • December 13, 2024
HUTCHMED’s Orpathys and Tagrisso Combination Secures the NMPA’s Breakthrough Therapy Designation for Lung Cancer

HUTCHMED’s Orpathys and Tagrisso Combination Secures the NMPA’s Breakthrough Therapy Designation for Lung Cancer

  • December 12, 2024
HUTCHMED and Innovent Report the NMPA’s Conditional Approval of Elunate Plus Tyvyt to Treat Advanced Endometrial Cancer

HUTCHMED and Innovent Report the NMPA’s Conditional Approval of Elunate Plus Tyvyt to Treat Advanced Endometrial Cancer

  • December 3, 2024
HUTCHMED Reports the NMPA’s NDA Acceptance of Tazemetostat for Treating Follicular Lymphoma

HUTCHMED Reports the NMPA’s NDA Acceptance of Tazemetostat for Treating Follicular Lymphoma

  • July 4, 2024
HUTCHMED Features the P-III (ESLIM-01) Study Data of Sovleplenib for Primary Immune Thrombocytopenia at EHA 2024

HUTCHMED Features the P-III (ESLIM-01) Study Data of Sovleplenib for Primary Immune Thrombocytopenia at EHA 2024

  • June 17, 2024
HUTCHMED Reports the P-III Trial Data and will Highlight Hematological Malignancy Programs at the EHA 2024

HUTCHMED Reports the P-III Trial Data and will Highlight Hematological Malignancy Programs at the EHA 2024

  • May 17, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.